Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease

The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Kidney international 2021-02, Vol.99 (2), p.466-474
Hauptverfasser:	Wolfe, Rory, Wetmore, James B., Woods, Robyn L., McNeil, John J., Gallagher, Hugh, Roderick, Paul, Walker, Rowan, Nelson, Mark R., Reid, Christopher M., Shah, Raj C., Ernst, Michael E., Lockery, Jessica E., Tonkin, Andrew M., Abhayaratna, Walter P., Gibbs, Peter, Wood, Erica M., Mahady, Suzanne E., Williamson, Jeff D., Donnan, Geoffrey A., Cloud, Geoffrey C., Murray, Anne M., Polkinghorne, Kevan R.
Format:	Artikel
Sprache:	eng
Schlagworte:	aspirin bleeding cardiovascular events chronic kidney disease elderly randomized clinical trial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!